Biogen, Eisai Alzheimer’s drug review delayed in EU
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's ...
Barclays Sticks to Its Sell Rating for Sage Group plc (SGE)
Barclays analyst Sven Merkt maintained a Sell rating on Sage Group plc (SGE – Research Report) today and set a price target of £10.80. The ...
Brokers Issue Forecasts for Plug Power FY2024 Earnings
Equities research analysts at Seaport Res Ptn issued their FY2024 earnings per share (EPS) estimates for shares of Plug Power in a research note issued to investors on Monday, January 27th. Seaport ...
Sage Group price target raised to 1,600 GBp from 1,500 GBp at Jefferies
Jefferies raised the firm’s price target on Sage Group (SGPYY) to 1,600 GBp from 1,500 GBp and keeps a Buy rating on the shares. The “most ...
Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...